COAG (Hemab Therapeutics Holdings) Total Liabilities: $371.42 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $46.54
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings Total Liabilities?

Hemab Therapeutics Holdings COAG +3.48% 11 Total Liabilities is $371.42 Mil as of Dec. 2025. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Hemab Therapeutics Holdings's Total Liabilities for the quarter that ended in Dec. 2025 was $371.42 Mil.

Hemab Therapeutics Holdings's quarterly Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($211.55 Mil) and increased from Dec. 2024 ($211.55 Mil) to Dec. 2025 ($371.42 Mil).

Hemab Therapeutics Holdings's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($211.55 Mil) and increased from Dec. 2024 ($211.55 Mil) to Dec. 2025 ($371.42 Mil).

Hemab Therapeutics Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Total Liabilities Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Total Liabilities
211.55 371.42

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
Total Liabilities 211.55 371.42
COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hemab Therapeutics Holdings's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.677+(0.573+360.168
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=371.42

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=194.783--176.635
=371.42

Hemab Therapeutics Holdings's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.677+(0.573+360.168
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=371.42

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=194.783--176.635
=371.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $371.42 Mil mean?
Hemab Therapeutics Holdings (COAG) has a Total Liabilities of $371.42 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hemab Therapeutics Holdings and its competitors.
Is Hemab Therapeutics Holdings' Total Liabilities too high?
Hemab Therapeutics Holdings' current Total Liabilities is $371.42 Mil. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Total Liabilities compare to ZLAB and SLS?
Hemab Therapeutics Holdings' Total Liabilities of $371.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current Total Liabilities is $371.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Total Liabilities of $371.42 Mil. The current Total Liabilities is $371.42 Mil. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Total Liabilities is $371.42 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.54
Price